LONDON (ShareCast) - AstraZeneca (NYSE: AZN - news) has completed the fourth phase of its clinical trial of diabetes treatment Onglyza.
Data from the SAVOR-TIMI-53 (Saxagliptin Assessment of Vascular Outcomes Recorded in Patients with Diabetes Mellitus) clinical trial is being analysed and will be submitted to the European Society of Cardiology (ESC) for potential presentation at the ESC Congress in September.
The study assessed adult patients with type 2 diabetes with either a history of established cardiovascular disease or multiple risk factors.
"[...]Onglyza met the primary safety objective of non inferiority, and did not meet the primary efficacy objective of superiority, for a composite endpoint of cardiovascular death, non-fatal myocardial infarction or non-fatal ischaemic stroke, when added to a patient's current standard of care (with or without other anti-diabetic therapies), as compared to placebo," the group said in a statement.
Onglyza aims to improve glycemic, or blood sugar, control in adults with type 2 diabetes.
This month Onglyza has been submitted for regulatory review in 95 countries and is approved in 86 countries including those in the European Union, the US, Canada, Mexico, India, Brazil and China.